A preliminary, randomized, double-blind, placebo-controlled trial of l-carnosine to improve cognition in schizophrenia
Schizophrenia Research, 10/26/2012
Chengappa KNR et al. – The authors conducted a preliminary study to test the hypothesis that l–carnosine, an antioxidant and anti–glycation agent which is co–localized and released with glutamate would improve executive dysfunction, a cognitive domain associated with glutamate. The preliminary findings suggest that l–carnosine merits further consideration as adjunctive treatment to improve executive dysfunction in persons with schizophrenia.
Seventy-five symptomatically stable adults with chronic schizophrenia were randomly assigned to l-carnosine as adjunctive treatment (2g/day) or a matched placebo in a double-blind manner for 3months.
Cognitive domains (executive dysfunction, memory, attention and motor speed) were assessed using a computerized battery at baseline, 4 and 12weeks, along with psychopathology ratings and safety parameters.
The l-carnosine group performed significantly faster on non-reversal condition trials of the set-shifting test compared with placebo but reversal reaction times and errors were not significantly different between treatments.
On the strategic target detection test, the l-carnosine group displayed significantly improved strategic efficiency and made fewer perseverative errors compared with placebo.
Other cognitive tests showed no significant differences between treatments.
Psychopathology scores remained stable.
The carnosine group reported more adverse events (30%) compared with the placebo group (14%).
Laboratory indices remained within acceptable ranges.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.